
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 10.570 | 10.570 | 0.000 |
Shares | 89.760 | 89.760 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 21.599 | 22.347 |
Price to Book | 3.305 | 2.714 |
Price to Sales | 3.937 | 3.330 |
Price to Cash Flow | 15.022 | 16.400 |
Dividend Yield | 1.780 | 2.102 |
5 Years Earnings Growth | 4.540 | 6.822 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 99.980 | 97.797 |
Technology | 0.020 | 0.380 |
Number of long holdings: 49
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Jiangsu Hengrui | CNE0000014W7 | 9.15 | 48.07 | -1.46% | |
Kelun Pharm A | CNE100000PW7 | 7.19 | 33.93 | -0.73% | |
Shanghai Allist Pharmaceuticals Co | CNE100005XJ7 | 6.73 | 85.20 | +0.18% | |
Sichuan Biokin Pharmaceutical | CNE100006FN4 | 6.63 | 260.00 | -2.26% | |
WuXi AppTec | CNE1000031K4 | 5.61 | 52.98 | +0.90% | |
APT Medical | CNE100004C45 | 5.47 | 432.82 | -1.73% | |
Beigene | CNE100005XT6 | 5.20 | 237.60 | -0.54% | |
Sinopep Allsino Bio Pharmaceutical Co | CNE1000051X5 | 4.78 | 48.19 | +0.29% | |
Eyebright Medical Technology Beijing | CNE1000041J5 | 4.50 | 100.99 | +0.15% | |
Shenzhen Mindray Bio-Medical | CNE100003G67 | 4.33 | 217.30 | -1.97% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
CIFM China Emerging Power Class A | 5.34B | 5.66 | -5.79 | 7.93 | ||
CIFM China Emerging Power Class H | 5.34B | 5.66 | -5.82 | - | ||
CIFM Technology Qian Yan Alloc | 2.67B | 2.65 | -6.55 | - | ||
China Intl AsiaPacific Advantage St | 2.43B | 2.62 | 2.96 | 4.96 | ||
China International China Advanced | 1.69B | 6.76 | -4.77 | 4.79 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review